Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2593)	9/21/2009 3:19:46 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

HNSN had already closed most of its July 7 DG on July 31, but today the stock is trading above its July 31 H and the volume although still below the 4,370,100 traded on July 7 is already above 4M The stock is still up 35.78% Volume is almost 9x its ADV. bigcharts.marketwatch.com It announced today that it received FDA clearance for its next generation Sensei X Robotic Catheter System. It introduced the Artisan Extend Control Catheter and the Lynx Robotic Ablation Catheter, which is a small, flexible irrigated ablation catheter for customers in Europe. The new Lynx robotic ablation catheter, which the company plans to launch in the European market, is supported by the Sensei X platform and leverages the navigation capability of the Artisan Extend catheter, but in a smaller and more flexible integrated profile for the treatment of AF and other electrophysiology disorders. It is expected to be available in the European Union within the first half of 2010, it is not currently available for sale in the U.S. HNSN has been trimming its losses and is expected to report a loss around $1.55 vs. the loss of $2.21 in 2008. For 2010 a further trim of the loss is expected.<g> The insiders hold around 30% of the shares and the short position is close to 7x its ADV.<g> The stock is not off from the longer term DT coming from its Oct 2007 H at $39.32 bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2593)	9/29/2009 12:18:02 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

MRNA is still up 6% with volume now above its ADV bigcharts.marketwatch.com It announced today that the U.S. Patent Office has issued a Notice of Allowance for its patent application covering an siRNA directed against a junctional adhesion molecule-1 gene. According to the company,the allowed claim has a broad array of potential applications, as a therapeutic approach for certain cancers, thrombosis, atherosclerosis, strokes, and hypertension; and it enhances the delivery of drugs across the skin and the blood-brain barrier. JAM-1 is reportedly a tight junction protein that plays a key role in maintaining epithelial and endothelial barrier functions, leukocyte transmigration and platelet adhesion and also functions as a pro-inflammatory molecule. The CEO said: "This allowance validates our patent strategy for our gene target portfolio, and reinforces our belief that we will obtain patent protection for our extensive library of siRNAs directed against more than 140 therapeutic gene targets." As prviously mentioned, MRNA has been trimming its losses and as was also mentioned, on April 2, it announced that it had sold its Manufacturing Business to Par Pharmaceuticals and it was concentrating on its RNAi projects. According to its CEO, Michael French, "that agreement eliminates all of MDRNA's non-RNAi expenses and represents the final step in the plan to create a company solely focused in the research and development of RNAi-based therapeutics." It is expected that MRNA reports on the two pending Qs will look good compared to 2008, and the 'target' remains unchanged.<g> bigcharts.marketwatch.com Bernard